<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005616" GROUP_ID="MUSKEL" ID="775603070211484524" MERGED_FROM="" MODIFIED="2009-05-13 02:37:54 +0200" MODIFIED_BY="Renea Johnston" REVIEW_NO="A022-R" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-05-13 02:37:54 +0200" MODIFIED_BY="Renea Johnston">
<TITLE MODIFIED="2008-08-04 02:18:00 +1000" MODIFIED_BY="[Empty name]">Corticosteroid injection for de Quervain's tenosynovitis</TITLE>
<CONTACT MODIFIED="2009-05-13 02:37:54 +0200" MODIFIED_BY="Renea Johnston"><PERSON ID="8416FB2082E26AA200433359414DDE58" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Cyriac</FIRST_NAME><LAST_NAME>Peters-Veluthamaningal</LAST_NAME><POSITION>General Practitioner</POSITION><EMAIL_1>raju@dds.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Antonius Deusinglaan 1</ADDRESS_1><CITY>Groningen</CITY><ZIP>9713 AV</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-50-3632963</PHONE_1><FAX_1>+31-50*3632964</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-05-13 02:37:54 +0200" MODIFIED_BY="Renea Johnston"><PERSON ID="8416FB2082E26AA200433359414DDE58" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Cyriac</FIRST_NAME><LAST_NAME>Peters-Veluthamaningal</LAST_NAME><POSITION>General Practitioner</POSITION><EMAIL_1>raju@dds.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Antonius Deusinglaan 1</ADDRESS_1><CITY>Groningen</CITY><ZIP>9713 AV</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-50-3632963</PHONE_1><FAX_1>+31-50*3632964</FAX_1></ADDRESS></PERSON><PERSON ID="5643" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Daniëlle</FIRST_NAME><MIDDLE_INITIALS>AWM</MIDDLE_INITIALS><LAST_NAME>van der Windt</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Senior Researcher</POSITION><EMAIL_1>dawm.vanderwindt@vumc.nl</EMAIL_1><EMAIL_2>d.van.der.windt@cphc.keele.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>EMGO Institute and Department of General Practice</DEPARTMENT><ORGANISATION>VU University Medical Centre</ORGANISATION><CITY>Amsterdam</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 444 8354</PHONE_1><PHONE_2>+44 1782 583 927</PHONE_2><FAX_1>+31 20 444 8361</FAX_1></ADDRESS></PERSON><PERSON ID="841ED8AD82E26AA200433359237C289A" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Winters</LAST_NAME><POSITION>General Practitioner</POSITION><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Antonius Deusinglaan 1</ADDRESS_1><CITY>Groningen</CITY><ZIP>9713 AV</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-50-4061834</PHONE_1></ADDRESS></PERSON><PERSON ID="841CB0CB82E26AA200433359CD4750A0" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Betty</FIRST_NAME><LAST_NAME>Meyboom-de Jong</LAST_NAME><POSITION>Head of the Dept. of General Practice</POSITION><EMAIL_1>B.Meyboom@med.umcg.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of General Practice</DEPARTMENT><ORGANISATION>University Medical Center Groningen</ORGANISATION><ADDRESS_1>Antonius Deusinglaan 1</ADDRESS_1><CITY>Groningen</CITY><ZIP>9713 AV</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31-50-3632963</PHONE_1><FAX_1>+31-50-3632964</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-05-12 14:46:52 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="5" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="4" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="5" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2009-05-12 14:48:47 +1000" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2009-05-12 14:48:35 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-12 14:48:35 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. CMSG ID A022-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-11-17 02:20:39 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<INTERNAL_SOURCES MODIFIED="2008-11-17 02:20:39 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<SOURCE MODIFIED="2008-11-17 02:14:56 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<NAME>Department of General Practice, University Medical Center Groningen</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-11-17 02:20:39 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<NAME>EMGO Institute, VU University Medical Center Amsterdam</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-05-12 16:06:09 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-05-12 14:44:06 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-21 11:44:22 +1100" MODIFIED_BY="[Empty name]">Corticosteroid injection for de Quervain's tenosynovitis</TITLE>
<SUMMARY_BODY MODIFIED="2009-05-12 14:44:06 +1000" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of Corticosteroid injections for de Quervain's tenosynovitis.</P>
<P>
<B>This review shows that in people with de Quervain's tenosynovitis,</B>
</P>
<P>We are uncertain whether Corticosteroid injections reduces pain because of the very low quality of the evidence.</P>
<P>
<B>What is de Quervain's tenosynovitis and what are corticosteroid injections?</B>
</P>
<P>De Quervain's tenosynovitis occurs when the tendon in your thumb and wrist becomes inflammed, painful and difficult to move.  A tendon is the part of your body that connects your muscles to your bones.  People with de Quervain's tenosynovitis have pain, tenderness, and swelling at the base of the thumb, especially when moving their wrist from side to side.   </P>
<P>Corticosteroid injections are shots with a needle into a joint (such as your wrist) or a tendon. Corticosteroids may work by reducing the inflammation of your wrist or thumb. The injection itself might also help to relieve the pressure on the tendon.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-05-12 15:24:14 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-05-05 05:17:05 +1000" MODIFIED_BY="Jenny Bellorini">
<P>De Quervain's tenosynovitis is a disorder characterised by pain on the radial (thumb) side of the wrist and functional disability of the hand. It can be treated by corticosteroid injection, splinting and surgery.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-05-06 09:57:31 +1000" MODIFIED_BY="[Empty name]">
<P>To summarise evidence on the efficacy and safety of corticosteroid injections for de Quervain's tenosynovitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-05-12 14:22:47 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, Issue 2), MEDLINE (1966 to April 2009), EMBASE (1956 to April 2009), CINAHL (1982 to April 2009), AMED (1985 to April 2009), DARE, Dissertation Abstracts and PEDro (physiotherapy evidence database).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-05-06 09:57:49 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised and controlled clinical trials evaluating the efficacy and safety of corticosteroid injections for de Quervain's tenosynovitis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-05-06 09:58:20 +1000" MODIFIED_BY="[Empty name]">
<P>After screening abstracts of studies identified by the search we obtained full text articles of studies which fulfilled the selection criteria. We extracted data using a predefined electronic form. We assessed the methodological quality of included trials by using the checklist developed by Jadad and the Delphi list. We extracted data on the primary outcome measures: treatment success; severity of pain or tenderness at the radial styloid; functional impairment of the wrist or hand; and outcome of Finkelstein's test, and the secondary outcome measures: proportion of patients with side effects; type of side effects and patient satisfaction with injection treatment.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-05-12 15:24:14 +1000" MODIFIED_BY="[Empty name]">
<P>We found one controlled clinical trial of 18 participants (all pregnant or lactating women) that compared one steroid injection with methylprednisolone and bupivacaine to splinting with a thumb spica. All patients in the steroid injection group (9/9) achieved complete relief of pain whereas none of the patients in the thumb spica group (0/9) had complete relief of pain, one to six days after intervention (number needed to treat to benefit (NNTB) = 1, 95% confidence interval (CI) 0.8 to 1.2). No side effects or local complications of steroid injection were noted.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-05-11 12:03:42 +1000" MODIFIED_BY="[Empty name]">
<P>The efficacy of corticosteroid injections for de Quervain's tenosynovitis has been studied in only one small controlled clinical trial, which found steroid injections to be superior to thumb spica splinting. However, the applicability of our findings to daily clinical practice is limited, as they are based on only one trial with a small number of included participants, the methodological quality was poor and only pregnant and lactating women participated in the study. No adverse effects were observed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-12 16:06:09 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-05-12 16:06:09 +1000" MODIFIED_BY="[Empty name]">
<P>De Quervain's tenosynovitis is a disorder that is characterised by pain, tenderness and swelling over the thumb side of the wrist (at the radial styloid process). It is especially associated with sideward movements of the wrist and often leads to impairment of thumb function. It is caused by impaired gliding of the tendons of the abductor pollicis longus (APL) and extensor pollicis brevis (EPB) muscles. These two tendons have almost the same function: the movement of the thumb away from the hand in the plane of the hand. This impaired gliding is most probably caused by thickening of the extensor retinaculum of the wrist (the thickened part of the general tendon sheath that holds the tendons of the extensor muscles in place).</P>
<P>De Quervain, a Swiss physician, is given credit for first describing this condition with a report of five cases in 1895 and eight additional cases in 1912. Although the term stenosing tenosynovitis is frequently used, the pathophysiology of de Quervain's disease does not involve inflammation. On histopathological examination the predominant features are degenerative changes (myxoid degeneration, fibrocartilagenous metaplasia and deposition of mucopolysaccharide). Pain is most probably elicited by mechanical impingement between the tendon and its narrowed fibro-osseous canal resulting in stimulation of nociceptors (<LINK REF="REF-Clarke-1998" TYPE="REFERENCE">Clarke 1998</LINK>).</P>
<P>De Quervain's tenosynovitis has tended to fall under umbrella terms such as repetitive strain injury (RSI) and work-related musculoskeletal disorders of the upper limb (WRMSDs-UL) (<LINK REF="REF-Sluiter-2001" TYPE="REFERENCE">Sluiter 2001</LINK>; <LINK REF="REF-Yassi-1997" TYPE="REFERENCE">Yassi 1997</LINK>). Several authors have proposed models in which complex interactions between genetic factors, biomechanical factors, biophysical characteristics and the psychological profile of a patient lead to WRMSDs (<LINK REF="REF-Aptel-2002" TYPE="REFERENCE">Aptel 2002</LINK>; <LINK REF="REF-Kumar-2001" TYPE="REFERENCE">Kumar 2001</LINK>). In a literature review of epidemiological studies strong evidence was found for links between some biomechanical risk factors and musculoskeletal disorders of the upper limb (<LINK REF="REF-Bernard-1997" TYPE="REFERENCE">Bernard 1997</LINK>). Some have questioned the role of work in causing de Quervain's tenosynovitis (<LINK REF="REF-Kay-2000" TYPE="REFERENCE">Kay 2000</LINK>).</P>
<P>In a large community based study from the United Kingdom, the prevalence of de Quervain's tenosynovitis was found to be 0.5% in men and 1.3% in women (<LINK REF="REF-Walker_x002d_Bone-2004" TYPE="REFERENCE">Walker-Bone 2004</LINK>). Specific upper limb disorders, such as de Quervain's tenosynovitis, tended to cluster within individuals more often than would be expected by chance and they were associated with greater disability and more use of health services than was nonspecific pain (<LINK REF="REF-Walker_x002d_Bone-2004" TYPE="REFERENCE">Walker-Bone 2004</LINK>). Data from the 1998 National Health Interview Survey/Occupational Health Supplement in the United States show an estimated 12-month period prevalence of tendinitis of the hand, wrist and elbow (including tendinitis, synovitis, tenosynovitis, de Quervain's disease and epicondylitis) of 0.31% amongst 127 million workers (<LINK REF="REF-Tanaka-2001" TYPE="REFERENCE">Tanaka 2001</LINK>). The annual cost of all WRMDs is estimated to range from 13 to 20 billion US dollars in the United States (<LINK REF="REF-Aptel-2002" TYPE="REFERENCE">Aptel 2002</LINK>).</P>
<P>Diagnosis of de Quervain's tenosynovitis is made by history and physical examination (<LINK REF="REF-Moore-1997" TYPE="REFERENCE">Moore 1997</LINK>). Symptoms consist of pain or tenderness at the radial styloid sometimes radiating to the thumb, forearm or shoulder, and on physical examination there might be swelling at the radial styloid with tenderness and crepitations on palpation. Finkelstein's test (deviating the wrist to the ulnar side, while grasping the thumb, resulting in pain) is typically positive. A positive Finkelstein's test has a between-observer repeatability (k) of 0.79 (<LINK REF="REF-Palmer-2000" TYPE="REFERENCE">Palmer 2000</LINK>). Unfortunately there is no gold standard diagnostic confirmatory test for de Quervain's tenosynovitis. In the literature a variety of terminology (e.g. tendinitis, peritendinitis, tenosynovitis, tenovaginitis) and  case definitions are used for this condition. In 1998, 2001 and 2007 efforts were made to construct reliable classifications and case definitions for soft tissue rheumatic disorders of the upper limb, including de Quervain's tenosynovitis (<LINK REF="REF-Harrington-1998" TYPE="REFERENCE">Harrington 1998</LINK>; <LINK REF="REF-Sluiter-2001" TYPE="REFERENCE">Sluiter 2001</LINK>; <LINK REF="REF-Huisstede-2007" TYPE="REFERENCE">Huisstede 2007</LINK>).</P>
<P>De Quervain's tenosynovitis can be treated by operative and non-operative treatment. Operative therapy (slitting or removing a strip of the tendon sheet) has been reported to be effective with a 91% cure rate, but is more invasive and associated with higher costs and the possibility of surgical complications (<LINK REF="REF-Ta-1999" TYPE="REFERENCE">Ta 1999</LINK>). Local anaesthetic and corticosteroid injections for musculoskeletal diseases became popular in the 1950s. The effectiveness of injection therapy is often attributed to the anti-inflammatory effects of corticosteroids but the exact mechanism of action remains unclear since on histopathologic examination inflammation cannot be demonstrated. In a systematic review of the effectiveness of corticosteroid injection for de Quervain's tenosynovitis, which included seven observational studies with a total of 459 wrists, 83% of the 226 wrists that received injection alone were cured, 61% of the 101 wrists that received injection and splint immobilisation were cured and 14% of those who received splinting alone were cured (<LINK REF="REF-Richie-2003" TYPE="REFERENCE">Richie 2003</LINK>). Other conservative treatment modalities, such as heat, cold, heat induction, strapping, splints, rest, massage, counter-irritants and medications were found not to be effective (<LINK REF="REF-Moore-1997" TYPE="REFERENCE">Moore 1997</LINK>). There are no reports available that describe the natural course of untreated de Quervain's tenosynovitis. Potential complications of local corticosteroid injections for musculoskeletal disorders such as de Quervain's tenosynovitis are local infection, post injection steroid flare (temporary worsening of pain in the first 24 to 36 hours after injection), atrophy (thinning) of subcutaneous fat, local depigmentation of the skin and, very rarely, tendon rupture (<LINK REF="REF-Cardone-2002" TYPE="REFERENCE">Cardone 2002</LINK>).</P>
<P>De Quervain's tenosynovitis can lead to marked disability and absence from work due to impaired functioning of the hand. Local corticosteroid injection has been suggested to be effective, safe and easy to apply therefore it was decided to perform a systematic review of the efficacy and safety of corticosteroid injections for de Quervain's tenosynovitis. Although the effectiveness of corticosteroid injections has been addressed in a previous systematic review (<LINK REF="REF-Richie-2003" TYPE="REFERENCE">Richie 2003</LINK>) a more comprehensive review, according to the standards of the Cochrane Collaboration, can provide valuable additional information. The <LINK REF="REF-Richie-2003" TYPE="REFERENCE">Richie 2003</LINK> review has major shortcomings: None of the identified studies were randomised or used controls, pooling of data was not performed in a standardised manner and it was stated only that the "MEDLINE and Ovid databases were searched". Search strategy, selection criteria and method of data synthesis were not specified and it was not clear which databases were searched on the Ovid platform.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-05-06 10:11:28 +1000" MODIFIED_BY="[Empty name]">
<P>To review systematically the evidence from clinical trials on the efficacy and safety of corticosteroid injections for de Quervain's tenosynovitis in adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-05-12 16:02:47 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-05-06 10:11:58 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-05-06 10:11:30 +1000" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) and controlled clinical trials (CCTs) evaluating injection therapy with corticosteroids were included in this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-05-06 10:11:36 +1000" MODIFIED_BY="[Empty name]">
<P>We only included studies containing a study population with a clinical diagnosis of de Quervain's tenosynovitis (pain and tenderness over the radial styloid and either pain at the radial styloid reproduced by resisted thumb extension or a positive Finkelstein's test result). We excluded studies addressing treatment of De Quervain's tenosynovitis of infectious origin.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-05-06 10:11:47 +1000" MODIFIED_BY="[Empty name]">
<P>We only included studies evaluating the effectiveness of local corticosteroid injections. The corticosteroid could be of any volume, type and concentration, a local anaesthetic agent could be added or not, and any injection technique could be used. We planned to include studies comparing corticosteroid injection to placebo, injection with local anaesthetic, injection with a different type of steroid, splinting, systemic analgesics (including NSAIDs), systemic steroids, surgery, combination treatments or no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-05-06 10:11:58 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>Treatment success: yes or no (we anticipated that the definition of treatment success may vary across trials).</LI>
<LI>Severity of pain or tenderness at the radial styloid.</LI>
<LI>Finkelstein's test negative: yes or no.</LI>
<LI>Functional status of the finger (using validated instruments to measure hand function).</LI>
<LI>Proportion of patients with adverse effects of steroid injection.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Patient satisfaction (using validated questionnaires).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-05-12 14:25:11 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases:<BR/>
</P>
<UL>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, Issue 2);</LI>
<LI>MEDLINE (1966 to April 2009, Ovid platform);</LI>
<LI>EMBASE (1956 to April 2009, Ovid platform);</LI>
<LI>CINAHL (1982 to April 2009, Ovid platform);</LI>
<LI>AMED (1985 to April 2009, Ovid platform);</LI>
<LI>PEDro, the physiotherapy evidence database (<A HREF="http://www.pedro.org.au">www.pedro.org.au</A>)</LI>
<LI>DARE (the Database of Abstracts of Reviews of Effectiveness; via <I>The Cochrane Library</I> 2009, Issue 2);</LI>
<LI>Dissertation abstracts.</LI>
</UL>
<P>The search strategy was developed for MEDLINE and modified as necessary for the other databases.</P>
<P>Complete search strategies for each database are provided in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>. We checked the references of all relevant publications (RCTs and reviews) to identify additional trials. We contacted content experts for unpublished data. There were no language restrictions.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-05-12 16:02:47 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Trial selection</HEADING>
<P>Two review authors independently selected trials for inclusion in this review based on the content of title and abstracts obtained through electronic searching of the databases. Each review author's selection was compared. We resolved any discrepancies in opinion about eligibility of a trial for this review by discussion and consensus between the two review authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality appraisal</HEADING>
<P>Two review authors independently extracted all data. We assessed each trial using a combination of an established quality assessment tool developed by Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) and the Delphi list (<LINK REF="REF-Verhagen-1998" TYPE="REFERENCE">Verhagen 1998</LINK>). The quality items assessed were:</P>
<OL>
<LI>randomisation;</LI>
<LI>concealment of allocation;</LI>
<LI>blinding of outcome assessor, care provider and patient;</LI>
<LI>reporting of withdrawals and drop-outs;</LI>
<LI>similarity of groups at baseline regarding the most important prognostic indicators;</LI>
<LI>specification of eligibility criteria;</LI>
<LI>availability of point estimates and measures of variability of primary outcome measures;</LI>
<LI>use of intention-to-treat analysis.</LI>
</OL>
<P>Each criterion was rated as adequate, inadequate or unclear (if insufficient information was presented).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two authors extracted details of the study population, interventions, treatment periods, length of follow up, complications, baseline demographic data and baseline and end of study outcomes using a pre-defined electronic form. We arbitrarily defined short-term outcomes as outcomes up to three months after the intervention and long-term outcomes as outcomes one year post-intervention or later. Referring back to the original article and establishing consensus resolved differences in data extraction. We consulted a third author to help resolve differences.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>For continuous data, we planned to calculate mean differences (MD) for outcomes measured using the same scale, and when the same outcomes were measured using different scales we were to use standardised mean differences (SMD). We planned to calculate absolute and relative difference in the change from baseline for continuous outcomes. We were to calculate absolute benefit as the improvement in the treatment group minus the improvement in the control group in original units. We were to calculate relative difference in the change from baseline as the absolute benefit divided by the baseline mean.</P>
<P>For dichotomous data, we planned to present the results for each study as relative risk and the number needed to treat. However, we made a post hoc decision to present the results as risk difference (RD) and number needed to treat (NNT) to benefit, as only one eligible study was identified and no events (treatment success) were observed in any of the participants in the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity</HEADING>
<P>To assess heterogeneity of trial results we planned to use the Cochrane Q-test and the I<SUP>2</SUP> statistic. In case of significant statistical heterogeneity we planned to explore potential sources by subgroup analysis. Since clinical and methodological diversity always occur in a meta-analysis, statistical heterogeneity is inevitable (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The test for heterogeneity is irrelevant to the choice of analysis; accordingly we used the random-effects model by default as it is identical to the fixed-effect model if there is no heterogeneity (I<SUP>2 </SUP>= 0%). In order to assess and quantify the possible magnitude of inconsistency (i.e. heterogeneity) across studies, we used the I<SUP>2</SUP> statistic with a rough guide for interpretation as follows: 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; 75% to 100% represents considerable heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>We planned the following subgroup analyses:</P>
<UL>
<LI>duration of symptoms at baseline: short if symptoms were present for up to four weeks, intermediate if symptoms were present for one month to one year, and long if symptoms were present for one year or longer;</LI>
<LI>trial design: RCT or controlled clinical trial.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical relevance tables</HEADING>
<P>We compiled a clinical relevance table for the primary outcomes to improve the readability of the review (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). For dichotomous outcomes, we calculated the absolute risk difference using the risk difference (RD) statistic, and the relative per cent change using the relative risk (RR) - 1 statistic in RevMan 5 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). We determined the number needed to treat (NNT) by calculating the inverse of the risk difference (RD).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Grading of evidence</HEADING>
<P>Finally we graded the evidence obtained in this systematic review according to the conventions proposed by the Cochrane Musculoskeletal Group (<LINK REF="REF-Tugwell-2004" TYPE="REFERENCE">Tugwell 2004</LINK>).</P>
<P>Platinum: a published systematic review that has at least two individual controlled trials each satisfying the following:</P>
<UL>
<LI>sample sizes of at least 50 per group - if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome;</LI>
<LI>blinding of patients and assessors for outcomes;</LI>
<LI>handling of withdrawals with &gt; 80% follow up (imputations based on methods such as Last Observation Carried Forward (LOCF) are acceptable);</LI>
<LI>concealment of treatment allocation.</LI>
</UL>
<P>Gold: at least one randomised clinical trial meeting all of the following criteria for the major outcome(s) as reported:</P>
<UL>
<LI>sample sizes of at least 50 per group - if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome;</LI>
<LI>blinding of patients and assessors for outcomes;</LI>
<LI>handling of withdrawals with &gt; 80% follow up (imputations based on methods such as LOCF are acceptable);</LI>
<LI>concealment of treatment allocation.</LI>
</UL>
<P>Silver: a systematic review or randomised trial that does not meet the above criteria. Silver ranking would also include evidence from at least one study of non-randomised cohorts that did and did not receive the therapy, or evidence from at least one high quality case-control study. A randomised trial with a 'head-to-head' comparison of agents would be considered silver level ranking unless a reference was provided to a comparison of one of the agents to placebo showing at least a 20% relative difference.</P>
<P>Bronze: the bronze ranking is given to evidence from at least one high quality case series without controls (including simple before/after studies in which patients act as their own control) or if the conclusion is derived from expert opinion based on clinical experience without reference to any of the foregoing (for example, argument from physiology, bench research or first principles).</P>
<P>This review will be updated two years after publication.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-05-12 14:46:32 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-05-12 14:46:32 +1000" MODIFIED_BY="[Empty name]">
<P>The electronic search resulted in retrieval of a total of 561 titles. We found no titles in PEDro. After screening the titles and abstracts, we selected five possible studies for further evaluation (<LINK REF="STD-Avci-2002" TYPE="STUDY">Avci 2002</LINK>; <LINK REF="STD-Goldfarb-2007" TYPE="STUDY">Goldfarb 2007</LINK>; <LINK REF="STD-Jirarattanaphochai-2004" TYPE="STUDY">Jirarattanaphochai 2004</LINK>; <LINK REF="STD-Kosuwon-1996" TYPE="STUDY">Kosuwon 1996</LINK>; <LINK REF="STD-Weiss-1994" TYPE="STUDY">Weiss 1994</LINK>). We retrieved full text articles of these five studies. We excluded four studies: one appeared to be a retrospective cohort study (<LINK REF="STD-Weiss-1994" TYPE="STUDY">Weiss 1994</LINK>) and three studies did not study the comparison of interest (in one study steroid injection was compared to steroid injection with additional oral medication (<LINK REF="STD-Jirarattanaphochai-2004" TYPE="STUDY">Jirarattanaphochai 2004</LINK>), in one study steroid injection was compared to steroid injection followed by wrist immobilisation in a splint (<LINK REF="STD-Kosuwon-1996" TYPE="STUDY">Kosuwon 1996</LINK>) and in one injection with steroid, lidocaine and bupivacaine alone were compared to injections with steroid, lidocaine, bupivacaine and bicarbonate (<LINK REF="STD-Goldfarb-2007" TYPE="STUDY">Goldfarb 2007</LINK>).</P>
<P>We were also aware of an ongoing randomised controlled trial assessing the effectiveness of corticosteroid injections in the setting of primary care, but the results of this study were not published when our search was performed (see '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>').</P>
<P>The included study (<LINK REF="STD-Avci-2002" TYPE="STUDY">Avci 2002</LINK>) was a controlled clinical study including 19 wrists in 18 pregnant or lactating women (five wrists of pregnant women, 14 of lactating women). It compared one injection of 0.25 ml of methylprednisolone (10 mg) with 0.5% bupivacaine to thumb spica splinting in a secondary care setting. Injections were given into the tendon-sheath. Diagnostic criteria were a tender nodule over the radial styloid and a positive Finkelstein's test result. The main outcome (complete relief of pain and a negative Finkelstein's test result) was measured one to six days after injection.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-05-06 10:14:29 +1000" MODIFIED_BY="[Empty name]">
<P>The included study used pseudo-randomisation (participants were randomised according to their order of application), there was no description of allocation concealment (but since there was alternate allocation it is likely that allocation concealment was inadequate) and participants, care providers and outcome assessors were not blinded. Withdrawals and drop-outs were reported and an intention-to-treat analysis was used, but it was not clear whether the two treatment groups were similar at baseline assessment regarding important prognostic indicators. The main outcome measure was "complete pain relief". No point estimates and measures of variability were presented for the outcome measures.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-05-06 10:14:41 +1000" MODIFIED_BY="[Empty name]">
<P>The only primary outcome measure assessed was complete relief of pain. All patients in the steroid injection group (9/9) achieved complete relief of pain and none of the patients in the thumb spica group (0/9) had complete relief of pain, one to six days after the intervention. The number needed to treat was thus 1 (95% CI 0.8 to 1.2). No side effects or local complications of steroid injection were noted (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-06 10:15:23 +1000" MODIFIED_BY="[Empty name]">
<P>In this review, which includes only one small controlled clinical trial (<LINK REF="STD-Avci-2002" TYPE="STUDY">Avci 2002</LINK>) with 18 participants, we found silver level evidence for the superiority of corticosteroid injection over thumb spica splinting within six days of injection. The number needed to treat was 1 for this intervention, which means that every participant treated with local corticosteroid injection for de Quervain's tenosynovitis achieves complete relief of pain within six days of treatment, while none of the participants treated with thumb spica splints achieves complete relief of pain.</P>
<P>The large effect size of steroid injections for de Quervain' tenosynovitis reported in this review  is consistent with findings in another systematic review which included only non-randomised studies (<LINK REF="REF-Richie-2003" TYPE="REFERENCE">Richie 2003</LINK>), in which a cure rate of 83% in 459 wrists receiving steroid injections alone was reported and no side effects were observed.</P>
<P>There are several important limitations to this review. Only one study was found, which included only 18 participants. The risk of bias may be considerable since the included study used pseudo-randomisation and allocation concealment and blinding were inadequate. The study also included a selected patient population (pregnant and lactating women), was carried out in a selected healthcare setting (specialist hospital care) and compared the effectiveness of local corticosteroid only to thumb spica splinting; generalisability was therefore limited. Long-term treatment effects were not assessed. Given the weak evidence base it is not possible to draw any firm conclusions regarding the effectiveness of steroid injections for de Quervain tenosynovitis. The applicability of the findings of this review to daily clinical practice is therefore limited and needs to be confirmed in larger, better designed randomised controlled trials of longer duration.</P>
<P>Several other issues regarding steroid injections for de Quervain's tenosynovitis remain to be clarified. There is no universally agreed case definition and there are no validated outcome measures for research purposes. Furthermore, the efficacy, safety and cost-effectiveness of steroid injection has never been compared directly to surgical therapy or a wait and see strategy. Long-term effectiveness has also never been studied.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-05-06 10:15:58 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-05-06 10:15:32 +1000" MODIFIED_BY="[Empty name]">
<P>There is silver level evidence that corticosteroid injections are superior to thumb spica splinting for relieving pain in the treatment of de Quervain's tenosynovitis, but the evidence is based on one very small controlled clinical trial of short duration and poor methodological quality, which included only pregnant and lactating women.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-05-06 10:15:58 +1000" MODIFIED_BY="[Empty name]">
<P>A case definition for de Quervain's tenosynovitis should be formulated for research purposes. Validated and relevant outcome measures for interventions for de Quervain's tenosynovitis should be developed. Future randomised controlled trials should have adequate sample sizes, better methodological quality (including adequate randomisation procedures and allocation concealment) and also study other types of participants (besides pregnant and lactating women). Longer follow up is needed and the findings should be reported according to the CONSORT statement. Studies are needed which compare corticosteroid injections to placebo and to surgery, and which compare different types and dosages of corticosteroids. Future studies should also address the natural course of de Quervain's tenosynovitis.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-05-06 10:16:09 +1000" MODIFIED_BY="[Empty name]">
<P>We would like to thank Louise Falzon (Trial Search Co-ordinator of the Cochrane Musculoskeletal Group) for her assistance in developing the search strategy and performing the searches and the Australian Editorial Base Co-ordinators for the Musculoskeletal Group, Miranda Cumpston and Renea Johnston, for their assistance in writing this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-05-06 10:16:14 +1000" MODIFIED_BY="[Empty name]">
<P>CP has conducted a randomised controlled trial (Groningen Hand and Wrist Injection Therapy Trial - HAWITT) assessing the efficacy and safety of corticosteroid injections for trigger finger, de Quervain's tenosynovitis and carpal tunnel syndrome in a primary care population. The HAWITT-trial is sponsored by an unrestricted educational grant by the pharmaceutical company Bristol-Myers Squibb.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-05-06 10:16:10 +1000" MODIFIED_BY="[Empty name]">
<P>CP: main author<BR/>DW: text of review, data extraction and analysis<BR/>JW: data extraction and analysis<BR/>BM: selection of studies</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-05-07 06:54:55 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<STUDIES MODIFIED="2009-05-07 06:03:19 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<INCLUDED_STUDIES MODIFIED="2009-05-05 18:18:05 +1000" MODIFIED_BY="Jenny Bellorini">
<STUDY DATA_SOURCE="PUB" ID="STD-Avci-2002" MODIFIED="2009-05-05 18:18:05 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Avci 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-05 18:18:05 +1000" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avci S, Yilmaz C, Sayli U</AU>
<TI>Comparison of nonsurgical treatment measures for de Quervain's disease of pregnancy and lactation</TI>
<SO>Journal of Hand Surgery</SO>
<YR>2002</YR>
<VL>27A</VL>
<NO>2</NO>
<PG>322-4</PG>
<IDENTIFIERS MODIFIED="2008-10-22 13:17:21 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-05-07 06:03:19 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<STUDY DATA_SOURCE="PUB" ID="STD-Goldfarb-2007" MODIFIED="2009-05-07 06:03:19 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Goldfarb 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-05-07 06:03:19 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldfarb CA, Gelberman RH, McKeon K, Chia B, Boyer MI</AU>
<TI>Extra-articular steroid injection: early patient response and the incidence of flare reaction</TI>
<SO>Journal of Hand Surgery</SO>
<YR>2007</YR>
<VL>32</VL>
<NO>10</NO>
<PG>1513-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-07 06:00:07 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jirarattanaphochai-2004" MODIFIED="2009-05-06 10:18:34 +1000" MODIFIED_BY="[Empty name]" NAME="Jirarattanaphochai 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-06 10:18:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jirarattanaphochai K, Saengnipanthkul S, Vipulakorn K, Jianmongkol S, Chatuparisute P, Jung S</AU>
<TI>Treatment of de Quervain disease with triamcinolone injection with or without nimesulide. A randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>2004</YR>
<VL>86-A</VL>
<NO>12</NO>
<PG>2700-6</PG>
<IDENTIFIERS MODIFIED="2009-05-05 18:18:16 +1000" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosuwon-1996" MODIFIED="2008-11-17 01:34:24 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Kosuwon 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-17 01:34:24 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosuwon J</AU>
<TI>Treatment of de Quervain tenosynovitis: a prospective randomized controlled study comparing the results of steroid injection with and without immobilization in a splint</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1996</YR>
<VL>1</VL>
<NO>1</NO>
<PG>5S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-08-04 21:22:20 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiss-1994" MODIFIED="2009-05-06 10:19:02 +1000" MODIFIED_BY="[Empty name]" NAME="Weiss 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-05-06 10:19:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiss AP, Akelman E, Tabatabai M</AU>
<TI>Treatment of de Quervain's disease</TI>
<SO>Journal of Hand Surgery</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>4</NO>
<PG>595-8</PG>
<IDENTIFIERS MODIFIED="2008-11-17 01:37:22 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-05-07 05:45:47 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Peters-2007" MODIFIED="2009-05-07 05:45:47 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Peters 2007" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-11-17 01:36:21 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<IDENTIFIER MODIFIED="2008-11-17 01:36:21 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" TYPE="ISRCTN" VALUE="53171398"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-05-07 06:54:55 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<ADDITIONAL_REFERENCES MODIFIED="2009-05-07 06:54:55 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<REFERENCE ID="REF-Aptel-2002" MODIFIED="2008-11-17 01:39:51 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Aptel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Aptel M, Aublet-Cuvelier A, Cnockaert JC</AU>
<TI>Work-related musculoskeletal disorders of the upper limb</TI>
<SO>Joint Bone Spine</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>6</NO>
<PG>546-55</PG>
<IDENTIFIERS MODIFIED="2008-11-17 01:38:35 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal"/>
</REFERENCE>
<REFERENCE ID="REF-Bernard-1997" MODIFIED="2009-05-05 18:31:27 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Bernard 1997" TYPE="OTHER">
<AU>Bernard BP</AU>
<TI>Musculoskeletal disorders and workplace factors: critical review of epidemiologic evidence for work-related musculoskeletal disorders of the neck, upper extremity and low back</TI>
<SO>US Department of Health and Human Services, DHHS (NIOSH) Publication No. 97-141</SO>
<YR>1997</YR>
<CY>Cincinnati (Ohio), USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cardone-2002" MODIFIED="2009-03-18 01:11:52 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Cardone 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cardone DA, Tallia AF</AU>
<TI>Joint and soft tissue injection</TI>
<SO>American Family Physician</SO>
<YR>2002</YR>
<VL>66</VL>
<NO>2</NO>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1998" MODIFIED="2009-05-06 10:19:26 +1000" MODIFIED_BY="[Empty name]" NAME="Clarke 1998" TYPE="JOURNAL_ARTICLE">
<AU>Clarke MT, Lyall HA, Grant JW, Matthewson MH</AU>
<TI>The histopathology of de Quervain's disease</TI>
<SO>Journal of Hand Surgery</SO>
<YR>1998</YR>
<VL>23B</VL>
<NO>6</NO>
<PG>732-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harrington-1998" MODIFIED="2008-11-17 01:51:59 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Harrington 1998" TYPE="JOURNAL_ARTICLE">
<AU>Harrington JM, Carter JT, Birrell L, Gompertz D</AU>
<TI>Surveillance case definitions for work related upper limb pain syndromes</TI>
<SO>Occupational and Environmental Medicine</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>4</NO>
<PG>264-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-05-05 18:18:45 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2009-05-05 18:18:45 +1000" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Huisstede-2007" MODIFIED="2009-05-07 06:54:50 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Huisstede 2007" TYPE="JOURNAL_ARTICLE">
<AU>Huisstede BM, Miedema HS, Verhagen AP, Koes BW, Verhaar JA</AU>
<TI>Multidisciplinary consensus on the terminology and classification of complaints of the arm, neck and/or shoulder</TI>
<SO>Occupational and Environmental Medicine</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>5</NO>
<PG>313-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2009-05-05 18:18:56 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-2000" MODIFIED="2008-11-17 01:59:42 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Kay 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kay NR</AU>
<TI>De Quervain's disease, changing pathology or changing perception?</TI>
<SO>Journal of Hand Surgery</SO>
<YR>2000</YR>
<VL>25B</VL>
<NO>1</NO>
<PG>65-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2001" MODIFIED="2008-11-17 02:00:30 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Kumar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kumar S</AU>
<TI>Theories of musculoskeletal injury causation</TI>
<SO>Ergonomics</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>1</NO>
<PG>17-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997" MODIFIED="2009-05-06 10:19:48 +1000" MODIFIED_BY="[Empty name]" NAME="Moore 1997" TYPE="JOURNAL_ARTICLE">
<AU>Moore JS</AU>
<TI>De Quervain's tenosynovitis: stenosing tenosynovitis of the first dorsal compartment</TI>
<SO>Journal of Occupational and Environmental Medicine</SO>
<YR>1997</YR>
<VL>39</VL>
<NO>10</NO>
<PG>990-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2000" MODIFIED="2009-03-15 20:22:31 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Palmer 2000" TYPE="JOURNAL_ARTICLE">
<AU>Palmer K, Walker-Bone K, Linaker C, Reading I, Kellingray S, Coggon D, et al</AU>
<TI>The Southampton examination schedule for the diagnosis of musculoskeletal disorders of the upper limb</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2000</YR>
<VL>59</VL>
<NO>1</NO>
<PG>5-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-05-06 10:20:31 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richie-2003" MODIFIED="2009-05-05 18:19:14 +1000" MODIFIED_BY="Jenny Bellorini" NAME="Richie 2003" TYPE="JOURNAL_ARTICLE">
<AU>Richie CA</AU>
<TI>Corticosteroid injection for treatment of de Quervain's tenosynovitis: a pooled quantitative literature evaluation</TI>
<SO>Journal of the American Board of Family Practitioners</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>2</NO>
<PG>102-6</PG>
<IDENTIFIERS MODIFIED="2009-05-05 18:19:14 +1000" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Sluiter-2001" MODIFIED="2008-11-17 02:05:01 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Sluiter 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sluiter JK, Rest KM, Frings-Dresen MH</AU>
<TI>Criteria document for evaluating the work-relatedness of upper-extremity musculoskeletal disorders</TI>
<SO>Scandinavian Journal of Work, Environment and Health</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>27 Suppl 1</NO>
<PG>1-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ta-1999" MODIFIED="2008-11-17 02:07:13 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Ta 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ta KT, Eidelman D, Thomson JG</AU>
<TI>Patient satisfaction and outcomes of surgery for de Quervain's tenosynovitis</TI>
<SO>Journal of Hand Surgery</SO>
<YR>1999</YR>
<VL>24A</VL>
<NO>5</NO>
<PG>1071-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanaka-2001" MODIFIED="2008-11-17 02:08:32 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Tanaka 2001" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka S, Petersen M, Cameron L</AU>
<TI>Prevalence and risk factors of tendinitis and related disorders of the distal upper extremity among U.S. workers: comparison to carpal tunnel syndrome</TI>
<SO>American Journal of Industrial Medicine</SO>
<YR>2001</YR>
<VL>39</VL>
<NO>3</NO>
<PG>328-35</PG>
<IDENTIFIERS MODIFIED="2008-11-17 02:08:32 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal"/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2004" MODIFIED="2009-05-06 10:21:23 +1000" MODIFIED_BY="[Empty name]" NAME="Tugwell 2004" TYPE="BOOK">
<AU>Tugwell P, Shea B, Boers M, Brooks P</AU>
<SO>Evidence-based Rheumatology</SO>
<YR>2004</YR>
<PB>BMJ Books</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verhagen-1998" MODIFIED="2008-07-18 01:36:01 +1000" MODIFIED_BY="[Empty name]" NAME="Verhagen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Verhagen AP, de Vet HCW, de Bie RA, Kessels AGH</AU>
<TI>The Delphi list; a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>12</NO>
<PG>1235-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker_x002d_Bone-2004" MODIFIED="2009-03-18 02:17:50 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NAME="Walker-Bone 2004" TYPE="JOURNAL_ARTICLE">
<AU>Walker-Bone K, Palmer KT, Reading I, Coggon D, Cooper C</AU>
<TI>Prevalence and impact of musculoskeletal disorders of the upper limb in the general population</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>4</NO>
<PG>642-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yassi-1997" MODIFIED="2009-05-06 10:21:38 +1000" MODIFIED_BY="[Empty name]" NAME="Yassi 1997" TYPE="JOURNAL_ARTICLE">
<AU>Yassi A</AU>
<TI>Repetitive strain injuries</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9056</NO>
<PG>943-7</PG>
<IDENTIFIERS MODIFIED="2008-11-17 02:11:38 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-12 15:21:47 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-12 15:21:47 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-05-06 10:16:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Avci-2002">
<CHAR_METHODS MODIFIED="2009-05-06 10:16:18 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled study: allocation of intervention based on order of application</P>
<P>Method of blinding unclear</P>
<P>Parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-06 10:16:23 +1000" MODIFIED_BY="[Empty name]">
<P>Secondary care</P>
<P>Pregnant (5 participants) or lactating (13 participants) women</P>
<P>Mean age 28 years (range: 20 to 36)</P>
<P>Inclusion criteria: tender nodule over the radial styloid and a positive Finkelstein's test result</P>
<P>Exclusion criteria: a past history of similar symptoms, systemic disorders such as diabetes or connective tissue diseases that cause tenosynovitis</P>
<P>Flow of participants: 18 enrolled, 18 randomised<BR/>9 randomised to corticosteroid + anaesthetic injection versus 9 randomised to thumb spica splinting<BR/>18 received allocated intervention<BR/>0 lost to follow up<BR/>18 participants analysed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-06 10:16:24 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: 1 injection of 0.25 ml methylprednisolone (10 mg) with 0.5% bupivacaine into the tendon sheath</P>
<P>Group 2: thumb spica splints worn during daytime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-15 20:51:13 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>Definition of treatment success: complete relief of pain and a negative Finkelstein test result</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-05 18:09:16 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-05-07 06:12:16 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-05-07 06:12:16 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal" STUDY_ID="STD-Goldfarb-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-07 06:12:16 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>Not comparison of interest: injection with steroid, lidocaine and bupivacaine alone was compared to injection with steroid, lidocaine, bupivacaine and bicarbonate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-06 10:16:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jirarattanaphochai-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-06 10:16:26 +1000" MODIFIED_BY="[Empty name]">
<P>Not comparison of interest: steroid injection was compared to steroid injection with additional oral medication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-06 10:16:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosuwon-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-06 10:16:28 +1000" MODIFIED_BY="[Empty name]">
<P>Not comparison of interest: steroid injection was compared to steroid injection followed by wrist immobilisation in a splint</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-06 10:16:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiss-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-06 10:16:29 +1000" MODIFIED_BY="[Empty name]">
<P>Not a randomised study: retrospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-05-07 06:46:42 +1000" MODIFIED_BY="Cyriac Peters-Veluthamaningal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-05-06 10:16:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peters-2007">
<CHAR_STUDY_NAME MODIFIED="2008-11-16 21:09:43 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>The Groningen Hand and Wrist Injection Therapy Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-05-05 18:09:53 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Randomised controlled study</P>
<P>Blinding of participants and outcome assessor</P>
<P>Parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-05 18:10:52 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Primary care</P>
<P>Adults</P>
<P>Inclusion criteria: a history of radial styloid tenderness and a positive Finkelstein's test and/or crepitus over APB and EPL tendons</P>
<P>Exclusion criteria: less than 18 years of age, presence of an absolute contraindication for corticosteroid injection, prior treatment in the last 6 months with steroid injection and/ or surgery at the same anatomical location, possible traumatic or neoplastic origin of symptoms, inability to fill in follow-up forms or absence of self-determination in the participant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-05 18:11:11 +1000" MODIFIED_BY="Jenny Bellorini">
<P>Group 1: 1 or 2 injections of 1 ml triamcinolonacetonide 10 mg/ml</P>
<P>Group 2: 1 or 2 injections of 1 ml 0.9 % NaCl</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-06 10:16:40 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Direct treatment response (consensus between physician and patient): no response; partial response, but not satisfactory, warranting further treatment; partial response, satisfactory, not warranting further treatment; complete resolution of symptoms and signs)</LI>
<LI>Perceived improvement (by patient): much worse, worse, not better/not worse, better, much better</LI>
<LI>Severity of pain at the radial styloid: 11-point numeric rating scale: 0 to 10</LI>
<LI>Functional improvement using the sub-items hand and finger function of the Dutch version of the second version of the Arthritis Impact Measurement Scale (DUTCH AIMS-2)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-16 21:15:05 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-05-06 10:16:45 +1000" MODIFIED_BY="[Empty name]">
<P>Cyriac Peters-Veluthamaningal, general practitioner. Department of General Practice, University Medical Center Groningen, Antonius Deusiglaan 1, 9713 AV Groningen, the Netherlands. E-mail: raju@dds.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-05-05 18:12:44 +1000" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>APB = abductor pollicis longus</P>
<P>EPL= extensor pollicis brevis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-05-12 15:21:47 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-05-12 15:21:47 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-12 15:21:47 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Avci-2002">
<DESCRIPTION>
<P>Unlikely to be adequately concealed, as allocation of intervention based on order of application</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-05-12 15:57:23 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-05-12 15:57:23 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-17 01:10:49 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">Clinical relevance for complete pain relief</TITLE>
<TABLE COLS="8" ROWS="2">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcome</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>n Patients/ n Trials</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Control event rate</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Absolute RD [95% CI]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Relative % change</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>NNTB [95% CI]</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Statistical significance</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of evidence</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Complete pain relief</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18/1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0% </P>
<P>0 out of 100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100 [81,119]</P>
<P>100 patients out of 100</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1800% (I) [27% (I), 28,300% (I)]</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 [0.8,1.2]</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Statistically significant</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Silver</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>RD = risk difference</P>
<P>I = Improvement</P>
<P>95% CI = 95% confidence interval</P>
<P>NNTB = number needed to treat to benefit<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-05-06 10:27:45 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-05-06 10:27:45 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>0.25 ml of methylprednisolone (10 mg) + 0.5% bupivacaine vs thumb spica splint</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-05-06 10:27:45 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.99" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Complete relief of symptoms</NAME>
<GROUP_LABEL_1>Corticosteroid injection</GROUP_LABEL_1>
<GROUP_LABEL_2>Thumb spica splint</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours splint</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours injection</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1910336588054424" CI_START="0.8089663411945576" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-04 22:33:04 +1000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.09746794344808964" STUDY_ID="STD-Avci-2002" TOTAL_1="9" TOTAL_2="9" VAR="0.0095" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-05-06 10:31:46 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-05-06 10:31:46 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-05-06 10:31:46 +1000" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-05 18:21:28 +1000" MODIFIED_BY="Jenny Bellorini">
<P>1. exp tenosynovitis/<BR/>2. tenosynovitis.tw.<BR/>3. exp TENDINITIS/<BR/>4. tend?nitis.tw.<BR/>5. peritendinitis.tw.<BR/>6. tendovaginitis.tw.<BR/>7. quervain$.tw.<BR/>8. exp Cumulative Trauma Disorders/<BR/>9. overuse syndrome$.tw.<BR/>10. repetit$ strain injur$.tw.<BR/>11. repetit$ motion disorder$.tw.<BR/>12. or/1-11<BR/>13. exp GLUCOCORTICOIDS/<BR/>14. glucocorticoid$.tw.<BR/>15. exp Adrenal Cortex Hormones/<BR/>16. corticoster$.tw.<BR/>17. exp Methylprednisolone/<BR/>18. methylprednisolone.tw.<BR/>19. exp BETAMETHASONE/<BR/>20. betamethasone.tw.<BR/>21. exp TRIAMCINOLONE/<BR/>22. triamcinolone.tw.<BR/>23. (steroid$ adj2 inject$).tw.<BR/>24. or/13-23<BR/>25. 12 and 24</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-05-05 18:23:16 +1000" MODIFIED_BY="Jenny Bellorini" NO="2">
<TITLE MODIFIED="2008-11-16 22:02:50 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-05 18:23:16 +1000" MODIFIED_BY="Jenny Bellorini">
<P>1. exp TENOSYNOVITIS/<BR/>2. tenosynovitis.tw.<BR/>3. exp TENDINITIS/<BR/>4. tend?nitis.tw.<BR/>5. peritendinitis.tw.<BR/>6. tendovaginitis.tw.<BR/>7. quervain$.tw.<BR/>8. exp Cumulative Trauma Disorder/<BR/>9. overuse syndrome$.tw.<BR/>10. repetit$ strain injur$.tw.<BR/>11. repetit$ motion disorder$.tw.<BR/>12. or/1-11<BR/>13. exp Glucocorticoid/<BR/>14. glucocorticoid$.tw.<BR/>15. exp Corticosteroid/<BR/>16. corticoster$.tw.<BR/>17. exp METHYLPREDNISOLONE/<BR/>18. methylprednisolone.tw.<BR/>19. exp BETAMETHASONE/<BR/>20. betamethasone.tw.<BR/>21. exp TRIAMCINOLONE/<BR/>22. triamcinolone.tw.<BR/>23. (steroid$ adj2 inject$).tw.<BR/>24. or/13-23<BR/>25. 12 and 24<BR/>26. random$.ti,ab.<BR/>27. factorial$.ti,ab.<BR/>28. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>29. placebo$.ti,ab.<BR/>30. (doubl$ adj blind$).ti,ab.<BR/>31. (singl$ adj blind$).ti,ab.<BR/>32. assign$.ti,ab.<BR/>33. allocat$.ti,ab.<BR/>34. volunteer$.ti,ab.<BR/>35. crossover procedure.sh.<BR/>36. double blind procedure.sh.<BR/>37. randomized controlled trial.sh.<BR/>38. single blind procedure.sh.<BR/>39. or/26-38<BR/>40. exp animal/ or nonhuman/ or exp animal experiment/<BR/>41. exp human/<BR/>42. 40 and 41<BR/>43. 40 not 42<BR/>44. 39 not 43</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-05-05 18:24:19 +1000" MODIFIED_BY="Jenny Bellorini" NO="3">
<TITLE MODIFIED="2008-11-16 22:04:05 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-05 18:24:19 +1000" MODIFIED_BY="Jenny Bellorini">
<P>1. exp tenosynovitis/<BR/>2. tenosynovitis.tw.<BR/>3. exp TENDINITIS/<BR/>4. tend?nitis.tw.<BR/>5. peritendinitis.tw.<BR/>6. tendovaginitis.tw.<BR/>7. quervain$.tw.<BR/>8. exp Cumulative Trauma Disorders/<BR/>9. overuse syndrome$.tw.<BR/>10. repetit$ strain injur$.tw.<BR/>11. repetit$ motion disorder$.tw.<BR/>12. or/1-11<BR/>13. exp GLUCOCORTICOIDS/<BR/>14. glucocorticoid$.tw.<BR/>15. exp Adrenal Cortex Hormones/<BR/>16. corticoster$.tw.<BR/>17. exp Methylprednisolone/<BR/>18. methylprednisolone.tw.<BR/>19. exp BETAMETHASONE/<BR/>20. betamethasone.tw.<BR/>21. exp TRIAMCINOLONE/<BR/>22. triamcinolone.tw.<BR/>23. (steroid$ adj2 inject$).tw.<BR/>24. or/13-23<BR/>25. 12 and 24</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-05-05 18:25:12 +1000" MODIFIED_BY="Jenny Bellorini" NO="4">
<TITLE MODIFIED="2008-11-16 22:04:54 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">AMED search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-05 18:25:12 +1000" MODIFIED_BY="Jenny Bellorini">
<P>1     exp Tenosynovitis/<BR/>2     tenosynovitis.tw.<BR/>3     tend?nitis.tw.<BR/>4     peritendinitis.tw.<BR/>5     tendovaginitis.tw.<BR/>6     quervain$.tw. (12)<BR/>7     overuse syndrome$.tw.<BR/>8     repetit$ strain injur$.tw.<BR/>9     repetit$ motion disorder$.tw.<BR/>10     or/1-9<BR/>11     exp Adrenal cortex hormones/<BR/>12     glucocorticoid$.tw.<BR/>13     corticoster$.tw.<BR/>14     methylprednisolone.tw.<BR/>15     betamethasone.tw.<BR/>16     triamcinolone.tw.<BR/>17     (steroid$ adj2 inject$).tw.<BR/>18     or/11-17</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-11-16 22:06:05 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NO="5">
<TITLE MODIFIED="2008-11-16 22:05:34 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">PEDro search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-16 22:06:05 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>Search 1</P>
<P>Tenosynovitis in Abstract or title and Body Part = hand or wrist</P>
<P>Search 2</P>
<P>Tendon in Abstract or title and Body Part = hand or wrist</P>
<P>Search 3</P>
<P>Quervain* in Abstract or title</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2009-05-05 18:26:20 +1000" MODIFIED_BY="Jenny Bellorini" NO="6">
<TITLE MODIFIED="2008-11-16 22:06:41 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-05 18:26:20 +1000" MODIFIED_BY="Jenny Bellorini">
<P>#1 MeSH descriptor Tenosynovitis explode all trees in MeSH products?<BR/>#2 tenosynovitis in All Fields in all products?<BR/>#3 MeSH descriptor Tendinitis explode all trees in MeSH products?<BR/>#4 tendonitis or tendinitis in All Fields in all products?<BR/>#5 peritendinitis in All Fields in all products?<BR/>#6 tendovaginitis in All Fields in all products?<BR/>#7 quervain* in All Fields in all products?<BR/>#8 MeSH descriptor Cumulative Trauma Disorders explode all trees in MeSH products?<BR/>#9 overuse syndrome* in All Fields in all products?<BR/>#10 repetit* next strain next injur* in All Fields in all products?<BR/>#11 repetit* next motion next disorder* in All Fields in all products?<BR/>#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)?<BR/>#13 MeSH descriptor Glucocorticoids explode all trees in MeSH products?<BR/>#14 glucocorticoid* in All Fields in all products?<BR/>#15 MeSH descriptor Adrenal Cortex Hormones explode all trees in MeSH products?<BR/>#16 corticoster* in All Fields in all products?<BR/>#17 MeSH descriptor Methylprednisolone explode all trees in MeSH products?<BR/>#18 Methylprednisolone in All Fields in all products?<BR/>#19 betamethasone in All Fields in all products?<BR/>#20 MeSH descriptor Betamethasone explode all trees in MeSH products?<BR/>#21 MeSH descriptor Triamcinolone explode all trees in MeSH products?<BR/>#22 TRIAMCINOLONE in All Fields in all products?<BR/>#23 steroid* near/2 inject* in All Fields in all products?<BR/>#24 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #21 OR #22 OR #23)?<BR/>#25 (#12 AND #24)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2009-05-05 18:27:20 +1000" MODIFIED_BY="Jenny Bellorini" NO="7">
<TITLE MODIFIED="2008-11-16 22:07:12 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">DARE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-05 18:27:20 +1000" MODIFIED_BY="Jenny Bellorini">
<P>#1 MeSH descriptor Tenosynovitis explode all trees in MeSH products?<BR/>#2 tenosynovitis in All Fields in all products?<BR/>#3 MeSH descriptor Tendinitis explode all trees in MeSH products?<BR/>#4 tendonitis or tendinitis in All Fields in all products?<BR/>#5 peritendinitis in All Fields in all products?<BR/>#6 tendovaginitis in All Fields in all products?<BR/>#7 quervain* in All Fields in all products?<BR/>#8 MeSH descriptor Cumulative Trauma Disorders explode all trees in MeSH products?<BR/>#9 overuse syndrome* in All Fields in all products?<BR/>#10 repetit* next strain next injur* in All Fields in all products?<BR/>#11 repetit* next motion next disorder* in All Fields in all products?<BR/>#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)?<BR/>#13 MeSH descriptor Glucocorticoids explode all trees in MeSH products?<BR/>#14 glucocorticoid* in All Fields in all products?<BR/>#15 MeSH descriptor Adrenal Cortex Hormones explode all trees in MeSH products?<BR/>#16 corticoster* in All Fields in all products?<BR/>#17 MeSH descriptor Methylprednisolone explode all trees in MeSH products?<BR/>#18 Methylprednisolone in All Fields in all products?<BR/>#19 betamethasone in All Fields in all products?<BR/>#20 MeSH descriptor Betamethasone explode all trees in MeSH products?<BR/>#21 MeSH descriptor Triamcinolone explode all trees in MeSH products?<BR/>#22 TRIAMCINOLONE in All Fields in all products?<BR/>#23 steroid* near/2 inject* in All Fields in all products?<BR/>#24 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #21 OR #22 OR #23)?<BR/>#25 (#12 AND #24)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2008-11-16 22:07:52 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal" NO="8">
<TITLE MODIFIED="2008-11-16 22:07:30 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">Dissertation abstracts search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-16 22:07:52 +1100" MODIFIED_BY="Cyriac Peters-Veluthamaningal">
<P>(Quervain* OR overuse syndrome* OR repetitive  strain OR repetitive motion) AND (glucocorticoid* OR corticoster*)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>